Wells Fargo names 13 stocks as overweight tactical ideas

Go back to Wells Fargo names 13 stocks as overweight tactical ideas

Citi Opens 90-Day Upside Catalyst Watch on Kymera Therapeutics (KYMR)

October 5, 2026 5:24 AM EDT

Citi analyst Geoff Meacham reiterated a Buy rating and $150.00 price target on Kymera Therapeutics (NASDAQ: KYMR)

Opens 90-Day Upside Catalyst Watch.

For an analyst ratings summary and ratings history on Kymera Therapeutics click here. For more ratings news on Kymera Therapeutics click here.

Shares of Kymera Therapeutics closed at $107.39 yesterday.

... More